In a phase 3 RCT of 127 patients with inoperable or persistent/recurrent CTEPH, macitentan 75 mg vs placebo did not improve 6-minute walk distance at week 28 (-16.1 m); the trial was stopped for futility at interim analysis. Discontinuation due to AEs 21.9% vs 7.9%.
RCTn = 127
Jenkins et al. Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension